Finally, while studies with other mAbs targeting LOXL2 and Notch2/3 receptors have not provided support for further studies in pancreatic cancer [121,203], the results of early phase trials evaluating the efficacy of the anti-DR5 mAbs conatumumab and tigatuzumab [73,125], the anti-CD40 mAb selicrelumab [135], and the anti-PSCA mAb AGS-1C4D4 [138] were encouraging and need to be validated in future studies. This evidence concerns the gene LOXL2 and pancreatic neoplasm.